All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Minimal Residual Disease Status Displays Association with PFS in CLL

August 1st 2024

Minimal residual disease status was associated with progression-free survival in chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Evorpacept Plus TRP Yields Durable Responses in HER2+ Gastric/GEJ Cancer

July 31st 2024

Evorpacept plus TRP generated clinically meaningful, robust, and durable responses in patients with previously treated HER2-positive gastric or GEJ cancer.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Model Validates Cost Savings With Cannabis in Mitigating Symptoms for Patients With Cancer

July 31st 2024

Blake Zenger, MBA, and Brooke Worster, MD, MS, FACP, detail a health care cost impacts model pertaining to the use of cannabis for therapy-related symptoms

Ongoing Research Aims to Bring Novel TROP-2–Directed ADCs to Metastatic TNBC

July 31st 2024

Sara M. Tolaney, MD, MPH, discusses the ongoing investigation of TROP-2–directed antibody-drug conjugates in triple-negative breast cancer.

Study Identifies Biomarker That Could Predict Chemotherapy Benefits for Colon Cancer Patients

July 31st 2024

Steven Chen, PhD, and colleagues identified a 10-gene biomarker that may predict benefit with adjuvant chemotherapy in stage II/III colon cancer.

FDA Grants Rare Pediatric Drug Designation to VCN-01 for Retinoblastoma

July 31st 2024

VCN-01 has received rare pediatric drug designation from the FDA for patients with retinoblastoma.

Pamrevlumab Fails to Provide OS Benefit in Pancreatic Cancer

July 31st 2024

Two late-stage trials investigating the efficacy and safety of pamrevlumab in pancreatic cancer failed to meet their primary end points of OS.

NCCN Recommends Imetelstat for Symptomatic Anemia in Lower-Risk MDS

July 31st 2024

The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.

Proactive Measures and a Multidisciplinary Approach Are Key for Diagnosis and Management of Sarcoma

July 31st 2024

Adam C. Berger, MD, FACS, discusses key messages for oncologists during Sarcoma Awareness Month.

Two Leading Experts Detail Hot Topics in GI Cancers to Be Presented at Upcoming ISGIO Meeting

July 31st 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

FDA Approves Subcutaneous Daratumumab Plus VRd in Multiple Myeloma

July 30th 2024

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

First-Line Avelumab Maintenance Extends OS in Advanced Urothelial Carcinoma With Low Tumor Burden

July 30th 2024

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

Fox Chase Cancer Center Researcher Yu ‘Sunny’ Liu, PhD, Receives NIH Grant to Study Genetic Links to Disease

July 30th 2024

Yu “Sunny” Liu, PhD, has received a grant from the NIGMS of the National Institutes of Health to study how misfolded human genome can cause disease.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Asciminib Receives FDA Priority Review for Newly Diagnosed Ph+ CP-CML

July 30th 2024

The FDA has granted priority review to asciminib for newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma

July 30th 2024

The addition of BNT111 to cemiplimab has produced clinical activity in anti-PD-(L)1 relapsed/refractory unresectable stage III or IV melanoma.

IMNN-01 Plus Perioperative Chemo Improves OS in Newly Diagnosed, Advanced Ovarian Cancer

July 30th 2024

IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.

Liquid Biopsy in Oncology: Have We Just Scratched the Surface?

July 30th 2024

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Uzzo Elucidates the Potential Role of KIM-1 as a Biomarker in RCC

July 30th 2024

Robert Uzzo, MD, details data from the IMmotion010 study on KIM-1 and how the biomarker could be used as well as future directions for investigating it in RCC.